Renovaro Biosciences Inc (NASDAQ:RENB) — Market Cap & Net Worth
Market Cap & Net Worth: Renovaro Biosciences Inc (RENB)
Renovaro Biosciences Inc (NASDAQ:RENB) has a market capitalization of $26.19 Million ($26.19 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24306 globally and #5232 in its home market, demonstrating a -20.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Renovaro Biosciences Inc's stock price $1.13 by its total outstanding shares 23180247 (23.18 Million). Also see Renovaro Biosciences Inc total assets for a full breakdown of the balance sheet.
Renovaro Biosciences Inc Market Cap History: 2015 to 2025
Renovaro Biosciences Inc's market capitalization history from 2015 to 2025. Data shows change from $90.40 Million to $26.19 Million (-12.47% CAGR). Also see RENB operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Renovaro Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #696 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2282 of 3165 |
Weight: Renovaro Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Renovaro Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Renovaro Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Renovaro Biosciences Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
812.98x
Renovaro Biosciences Inc's market cap is 812.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.77 Million | $42.77K | -$1.74 Million | 812.98x | N/A |
Competitor Companies of RENB by Market Capitalization
Companies near Renovaro Biosciences Inc in the global market cap rankings as of September 17, 2026. Review Renovaro Biosciences Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Renovaro Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Renovaro Biosciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Renovaro Biosciences Inc's market cap moved from $90.40 Million to $ 26.19 Million, with a yearly change of -12.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $26.19 Million | +35.25% |
| 2024 | $19.37 Million | -73.64% |
| 2023 | $73.48 Million | +207.77% |
| 2022 | $23.88 Million | -85.87% |
| 2021 | $168.98 Million | +147.12% |
| 2020 | $68.38 Million | -41.24% |
| 2019 | $116.36 Million | -28.28% |
| 2018 | $162.26 Million | +47.37% |
| 2017 | $110.11 Million | +216.67% |
| 2016 | $34.77 Million | -61.54% |
| 2015 | $90.40 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Renovaro Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.19 Million USD |
| MoneyControl | $26.19 Million USD |
| MarketWatch | $26.19 Million USD |
| marketcap.company | $26.19 Million USD |
| Reuters | $26.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more